FDA Submits Proposed Information Collection for Enhanced Review Transparency and Communication

Summary

The Food and Drug Administration (FDA) has submitted a proposed collection of information to the Office of Management and Budget (OMB) for review and clearance, focusing on the Program for Enhanced Review Transparency and Communication for New Molecular Entity New Drug Applications and Original Biologics License Applications under the Prescription Drug User Fee Act.